Company Overview and News
KUALA LUMPUR, July 19 ― Bursa Malaysia closed higher today for the ninth consecutive day with small-capitalised (cap) as well as mid-sized cap conventional and shariah-related stocks being the flavour of the day among traders, amid mixed regional bourses’ performance, said a dealer.
PBLOF 1589 5819 1295 BSMAF 9334 1818
KUALA LUMPUR (July 19): The FBM KLCI pared some its gains at the midday break today and was up 0.44%, against the backdrop of higher regional markets.
PBLOF MLYBY MLYNF 7113 TPGVF 1295 3794 5014 9334 0131 TGLVY 1155 4588 3867 8613 6459 5819 MYPRY 1929
KUALA LUMPUR (July 18): The FBM KLCI reversed its earlier losses and rose 0.31% at midday break, tracking gains at most Asian markets.
HLFBF 7172 PBLOF 7053 1082 7087 1295 9334 7123 0143 4863 0156 8613 0026 6888 5819 AXXTF MYTEF 2836
KUALA LUMPUR (July 18): The FBM KLCI pared down its earlier losses substantially at mid-morning today, tracking the advance at key Asian markets.
7172 PBLOF 7053 8133 7087 1295 7153 7123 7079 0176 4588 3026 6645 5819
KUALA LUMPUR (July 16): The FBM KLCI paused for a breather at midday break today, tracking regional markets as China’s economic growth showed a modest slowdown.
UPBMF 7113 TPGVF BATS 4162 2291 5202 7153 2089 5014 CIMDF TGLVY 1023 3204 4588 3026 5819 MYPRY
KUALA LUMPUR, July 12 — Bursa Malaysia extended gains for a fourth consecutive day with the benchmark index closing at a near three-week high today, bolstered by positive regional sentiment and strong gains in index-linked counters led by Maybank.
HLFBF 3204 PBLOF 5225 3867 5819 1082 1295 Q0F BSMAF IHHHF 1818
KUALA LUMPUR (July 12): The FBM KLCI reversed its earlier losses and climbed 0.44% at midday break, tracking regional markets, lifted by gains including at banking heavyweights Malayan Banking Bhd and Pulic Bank Bhd.
PBLOF MLYBY SPMXF MLYNF BATS 4162 1295 7153 5168 1155 KLKBY 3204 2445 SPMXY 4456 3301 3867 7205 0026 1899 5819 HRGHY
KUALA LUMPUR (July 12): The FBM KLCI remained presured at mid-morning today, tracking regional markets as market sentiment stayed tepid with the spectre of a U.S.-China trade war still hanging over global markets.
HLFBF 7073 PBLOF 7113 4065 BATS TPGVF 4162 1295 7153 2089 KLKBY 3867 6139 7668 HRGHY UPBMF 1082 5168 0131 TGLVY 5139 2445 5216 0026 0900 1899 5819
KUALA LUMPUR (July 12): The FBM KLCI halted its ascend in ear;y trade this morning as regional markets stayed under pressure with escalating worries over the U.S.-China trade war.
HLFBF TGLVY 4588 3301 3867 5819 1082 7113 TPGVF BATS 4162 GEBHF
KUALA LUMPUR (July 6): The FBM KLCI fell 0.37% art mid-morning today, dragged by index-linked banking stocks against the backdrop of mixed regional markets.
MLYBY MLYNF UPBMF 4065 BATS 4162 2089 7055 7154 5255 CIMDF 1155 5139 1023 0900 0026 6888 5819 AXXTF
KUALA LUMPUR, July 5 — A taxi driver was fined RM8,000 by a magistrate’s court here today after pleading guilty to a charge of aiding to hide money owned by a chef into his bank account three years ago.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...